brexucabtagene autoleucel,blinatumomab
gilead,amgen
['zuma-3', 'blina ', 'brexu-cel']
congress|#asco23|bijal shah presented the 3-yr outcomes of zuma-3 by age, prior therapy, and subsequent allosct. brexu-cel showed benefit across all subgroups of adults with r/r b-all, though pts with vs w/o prior blina had a lower os. further study is needed
#allsm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm